Atyr PHARMA (NASDAQ:ATYR) Receives “Buy” Rating from HC Wainwright

Atyr PHARMA (NASDAQ:ATYR)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $35.00 price objective on the stock.

Atyr PHARMA Stock Performance

Atyr PHARMA stock opened at $1.98 on Thursday. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.02. Atyr PHARMA has a 12-month low of $1.08 and a 12-month high of $2.50. The stock has a market cap of $136.64 million, a P/E ratio of -2.20 and a beta of 1.25.

Insider Buying and Selling

In related news, Director Paul Schimmel acquired 52,300 shares of Atyr PHARMA stock in a transaction that occurred on Wednesday, July 24th. The shares were purchased at an average cost of $1.93 per share, for a total transaction of $100,939.00. Following the acquisition, the director now owns 413,023 shares in the company, valued at $797,134.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 3.70% of the stock is currently owned by company insiders.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company’s lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.